[go: up one dir, main page]

SG11201600987TA - Compositions and methods for modulating rna - Google Patents

Compositions and methods for modulating rna

Info

Publication number
SG11201600987TA
SG11201600987TA SG11201600987TA SG11201600987TA SG11201600987TA SG 11201600987T A SG11201600987T A SG 11201600987TA SG 11201600987T A SG11201600987T A SG 11201600987TA SG 11201600987T A SG11201600987T A SG 11201600987TA SG 11201600987T A SG11201600987T A SG 11201600987TA
Authority
SG
Singapore
Prior art keywords
compositions
methods
modulating rna
modulating
rna
Prior art date
Application number
SG11201600987TA
Inventor
Fatih Ozsolak
Caroline Woo
Original Assignee
Rana Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rana Therapeutics Inc filed Critical Rana Therapeutics Inc
Publication of SG11201600987TA publication Critical patent/SG11201600987TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
SG11201600987TA 2013-08-16 2014-08-15 Compositions and methods for modulating rna SG11201600987TA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361866989P 2013-08-16 2013-08-16
US201361898461P 2013-10-31 2013-10-31
US201462010417P 2014-06-10 2014-06-10
PCT/US2014/051331 WO2015023975A1 (en) 2013-08-16 2014-08-15 Compositions and methods for modulating rna

Publications (1)

Publication Number Publication Date
SG11201600987TA true SG11201600987TA (en) 2016-03-30

Family

ID=52467112

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201600987TA SG11201600987TA (en) 2013-08-16 2014-08-15 Compositions and methods for modulating rna

Country Status (13)

Country Link
US (8) US20150050738A1 (en)
EP (1) EP3033424A4 (en)
JP (1) JP2016528897A (en)
KR (1) KR20160036065A (en)
CN (1) CN105658797A (en)
AU (2) AU2014306416B2 (en)
BR (1) BR112016003127A2 (en)
CA (1) CA2921556A1 (en)
EA (1) EA201690403A1 (en)
IL (1) IL244081A0 (en)
MX (1) MX2016002044A (en)
SG (1) SG11201600987TA (en)
WO (1) WO2015023975A1 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE12722942T1 (en) 2011-03-31 2021-09-30 Modernatx, Inc. RELEASE AND FORMULATION OF MANIPULATED NUCLEIC ACIDS
ES2987057T3 (en) 2011-06-08 2024-11-13 Translate Bio Inc Cleavable lipids
WO2014152031A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Ribonucleic acid purification
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
HUE056760T2 (en) 2013-07-11 2022-03-28 Modernatx Inc Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
WO2015023941A1 (en) 2013-08-16 2015-02-19 Rana Therapeutics, Inc. Oligonucleotides targeting euchromatin regions of genes
EP3033425A4 (en) * 2013-08-16 2017-07-26 Rana Therapeutics, Inc. Compositions and methods for modulating expression of frataxin
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2016011222A2 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Circular polynucleotides
WO2016011226A1 (en) * 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
CN107109411B (en) 2014-10-03 2022-07-01 冷泉港实验室 Targeted increase in nuclear gene export
US10822369B2 (en) 2014-11-14 2020-11-03 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of proteins
CA2976576A1 (en) * 2015-02-13 2016-08-18 Translate Bio Ma, Inc. Compositions and methods for modulating rna
WO2016130943A1 (en) 2015-02-13 2016-08-18 Rana Therapeutics, Inc. Hybrid oligonucleotides and uses thereof
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
PL3350333T3 (en) 2015-09-17 2022-03-07 Modernatx, Inc. Polynucleotides containing a stabilizing tail region
EP3359685A1 (en) 2015-10-09 2018-08-15 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
AU2016340183A1 (en) 2015-10-16 2018-04-19 Modernatx, Inc. mRNA cap analogs and methods of mRNA capping
DK3362461T3 (en) 2015-10-16 2022-05-09 Modernatx Inc MRNA-CAP ANALOGS WITH MODIFIED PHOSPHAT BINDING
EP3368089B1 (en) * 2015-10-26 2025-11-05 Translate Bio Ma, Inc. Nanoparticle formulations for delivery of nucleic acid complexes
EP4163374A1 (en) 2015-11-23 2023-04-12 The Regents of the University of California Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
US11083745B2 (en) 2015-12-14 2021-08-10 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
US10689689B2 (en) * 2015-12-28 2020-06-23 Roche Molecular Systems, Inc. Generic method for the stabilization of specific RNA
EP3825400B1 (en) 2016-04-08 2024-12-25 Translate Bio, Inc. Multimeric coding nucleic acid and uses thereof
WO2017188898A1 (en) 2016-04-29 2017-11-02 Nanyang Technological University G-quadruplex-containing antisense oligonucleotides
CN107841510B (en) * 2016-09-20 2021-02-09 中国科学院青岛生物能源与过程研究所 Method for controlling expression ratio of different genes horizontally after transcription of prokaryotic cell
JP7288854B2 (en) * 2016-10-07 2023-06-08 セカルナ・ファーマシューティカルズ・ゲーエムベーハー・ウント・コ・カーゲー A novel approach to treat cancer
WO2018089688A1 (en) 2016-11-09 2018-05-17 Jinjun Shi Restoration of tumor suppression using mrna-based delivery system
WO2018089527A1 (en) 2016-11-09 2018-05-17 Intrexon Corporation Frataxin expression constructs
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
CN106813960A (en) * 2016-12-26 2017-06-09 广州和实生物技术有限公司 Free RNA protective agents of a kind of blood and preparation method and application
AU2018265022A1 (en) 2017-05-10 2019-11-21 The Regents Of The University Of California Directed editing of cellular RNA via nuclear delivery of CRISPR/Cas9
SMT202400071T1 (en) 2017-08-25 2024-03-13 Stoke Therapeutics Inc Antisense oligomers for treatment of conditions and diseases
WO2019093423A1 (en) * 2017-11-09 2019-05-16 国立大学法人東京大学 METHOD FOR mRNA STABILIZATION
BR112020011670A2 (en) 2017-12-15 2020-11-17 Flagship Pioneering Innovations Vi, Llc. compositions comprising circular polyribonucleotides and their uses
US11661601B2 (en) * 2018-03-22 2023-05-30 Ionis Pharmaceuticals, Inc. Methods for modulating FMR1 expression
CN108531496B (en) * 2018-04-04 2020-11-06 江南大学 DNA for increasing exogenous gene mRNA quantity and application thereof
JP2021523227A (en) 2018-05-04 2021-09-02 ストーク セラピューティクス，インク． Methods and Compositions for the Treatment of Cholesteryl Ester Accumulation
EP3852814A4 (en) * 2018-09-20 2022-09-14 ModernaTX, Inc. Compositions and methods for delivery of nucleic acids
CN111041001B (en) * 2018-10-15 2023-02-28 上海行深生物科技有限公司 Safe coxsackie virus for treating KRAS mutant tumor and pharmaceutical composition thereof
JP2022515211A (en) 2018-12-20 2022-02-17 アールネイティブズ・インコーポレイテッド Synthetic microRNA mimic
KR20210142678A (en) 2019-03-25 2021-11-25 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 Compositions comprising modified circular polyribonucleotides and uses thereof
WO2020214806A1 (en) * 2019-04-16 2020-10-22 The Regents Of The University Of California Protein translational control
CN111041025B (en) 2019-12-17 2021-06-18 深圳市瑞吉生物科技有限公司 mRNA targeting molecule based on binding N-acetylgalactosamine polypeptide and preparation method thereof
CN112111524B (en) * 2020-01-10 2024-02-27 深圳瑞吉生物科技有限公司 Preparation methods of mRNA-GalNAc targeting molecules and their in vivo delivery systems and applications
CA3173647A1 (en) 2020-05-11 2021-11-18 Isabel AZNAREZ Opa1 antisense oligomers for treatment of conditions and diseases
CN111744019B (en) 2020-07-01 2023-08-04 深圳瑞吉生物科技有限公司 Mannose-based mRNA targeted delivery system and its application
EP4560021A1 (en) * 2022-07-19 2025-05-28 Shenzhen Shenxin Biotechnology Co., Ltd. Mrna for sars-cov-2 s protein and use thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US546A (en) * 1838-01-06 Loom for weaving knotted counterpanes and other fabrics in which the
US21020A (en) * 1858-07-27 Improved combination of the needle and sun-dial to ascertain time
US13402A (en) * 1855-08-07 Forming screw-threads
US1099771A (en) * 1913-05-26 1914-06-09 Guy P Slater Derrick.
US6111094A (en) * 1990-08-14 2000-08-29 Isis Pharmaceuticals Inc. Enhanced antisense modulation of ICAM-1
US20040033977A1 (en) * 1990-08-14 2004-02-19 Bennett C. Frank Oligonucleotide modulation of cell adhesion
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
DE69321122D1 (en) * 1992-07-02 1998-10-22 Hybridon Inc SELF-STABILIZED OLIGONUCLEOTIDES AS THERAPEUTICS
AU7401394A (en) * 1993-07-20 1995-02-20 University Of Massachusetts Medical Center In vivo nucleic acid hybridization method
US5962332A (en) * 1994-03-17 1999-10-05 University Of Massachusetts Detection of trinucleotide repeats by in situ hybridization
US5866331A (en) * 1995-10-20 1999-02-02 University Of Massachusetts Single molecule detection by in situ hybridization
US5962675A (en) * 1996-02-13 1999-10-05 Ribozyme Pharmaceuticals, Inc. Chemical syntheses of 2'-O-methoxy purine nucleosides
US6261836B1 (en) * 1996-10-01 2001-07-17 Geron Corporation Telomerase
WO1998048054A1 (en) * 1997-04-23 1998-10-29 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
WO1999001139A1 (en) * 1997-07-03 1999-01-14 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
WO1999010509A1 (en) * 1997-08-22 1999-03-04 The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services, National Institutes Of Health Polynucleotide inhibition of rna destabilization and sequestration
US6322978B1 (en) * 1998-04-20 2001-11-27 Joslin Diabetes Center, Inc. Repeat polymorphism in the frataxin gene and uses therefore
WO2001000821A1 (en) * 1999-06-23 2001-01-04 Angiogene Inc. Antisense oligonucleotide modulating cyclin e gene expression and therapeutic uses thereof
US20020009724A1 (en) * 1999-12-08 2002-01-24 Robert Schlegel Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
EP1130121A3 (en) * 2000-01-26 2003-04-16 Nisshinbo Industries Inc. Immobilized nucleic acid and method for detecting nucleic acid
US6503756B1 (en) * 2000-09-22 2003-01-07 Isis Pharmaceuticals, Inc. Antisense modulation of syntaxin 4 interacting protein expression
US20030125273A1 (en) * 2001-12-05 2003-07-03 Isis Pharmaceuticals Inc, Antisense modulation of MHC class II transactivator expression
GB0101397D0 (en) * 2001-01-19 2001-03-07 Amersham Pharm Biotech Uk Ltd Suppression of non-specific nucleic acid amplication
AU2002317437A1 (en) * 2001-05-18 2002-12-03 Cureon A/S Therapeutic uses of lna-modified oligonucleotides in infectious diseases
US20050048529A1 (en) * 2002-02-20 2005-03-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US7399590B2 (en) * 2002-02-21 2008-07-15 Asm Scientific, Inc. Recombinase polymerase amplification
US20040023906A1 (en) * 2002-08-01 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of phosphotyrosyl phosphatase activator expression
PT2264172T (en) * 2002-04-05 2017-12-06 Roche Innovation Ct Copenhagen As Oligomeric compounds for the modulation of hif-1alpha expression
US20040097441A1 (en) * 2002-11-16 2004-05-20 Isis Pharmaceuticals Inc. Modulation of NIMA-related kinase 6 expression
US20040005565A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of livin expression
EP2957568B1 (en) * 2002-11-05 2016-12-21 Ionis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
EP2213738B1 (en) * 2002-11-14 2012-10-10 Dharmacon, Inc. siRNA molecules targeting Bcl-2
DK2284269T3 (en) * 2002-11-18 2017-10-23 Roche Innovation Ct Copenhagen As Antisense design
US20040110153A1 (en) * 2002-12-10 2004-06-10 Affymetrix, Inc. Compleixity management of genomic DNA by semi-specific amplification
US7750144B2 (en) * 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
US20050014168A1 (en) * 2003-06-03 2005-01-20 Arcturus Bioscience, Inc. 3' biased microarrays
PE20050469A1 (en) * 2003-09-18 2005-09-10 Lilly Co Eli MODULATION OF THE EXPRESSION OF EIF4E
US20050108783A1 (en) * 2003-09-23 2005-05-19 Chihiro Koike Porcine invariant chain protein, full length cDNA, genomic organization, and regulatory region
US20050261217A1 (en) * 2004-05-18 2005-11-24 Isis Pharmaceuticals Inc. Modulation of pumilio 1 expression
US20050261216A1 (en) * 2004-05-18 2005-11-24 Isis Pharmaceuticals Inc. Modulation of Nanos 1 expression
CA2569419A1 (en) * 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
US20050287539A1 (en) * 2004-06-29 2005-12-29 Emmanuel Labourier Methods and compositions for preparing capped RNA
DE102004034987A1 (en) * 2004-07-16 2006-02-02 Carl Zeiss Jena Gmbh Scanning microscope and use
US7718625B2 (en) * 2005-01-27 2010-05-18 University Of South Florida Polynucleotides targeted against the extended 5′-UTR region of argininosuccinate synthase and uses thereof
WO2006082826A1 (en) * 2005-02-02 2006-08-10 Eisai R & D Management Co., Ltd. METHOD OF IDENTIFYING PURKINJE CELL TARGETING Corl2 GENE
US8999943B2 (en) * 2005-03-14 2015-04-07 Board Of Regents, The University Of Texas System Antigene oligomers inhibit transcription
JP5066095B2 (en) * 2005-11-17 2012-11-07 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Regulation of gene expression by oligomers targeted to chromosomal DNA
EP1966377A2 (en) * 2005-11-21 2008-09-10 Isis Pharmaceuticals, Inc. Modulation of eif4e-bp2 expression
US8685899B2 (en) * 2007-02-14 2014-04-01 Genisphere Inc. Methods, reagents and kits for detection of nucleic acid molecules
CN101679978B (en) * 2007-05-22 2016-05-04 阿克丘勒斯治疗公司 Hydroxymethyl-substituted RNA oligonucleotides and RNA complexes
US20090082297A1 (en) * 2007-06-25 2009-03-26 Lioy Daniel T Compositions and Methods for Regulating Gene Expression
EP2173913A4 (en) * 2007-08-03 2010-09-01 Biocept Inc In-situ hybridization to detect rna and dna markers
US20110009466A1 (en) * 2007-08-29 2011-01-13 President And Fellows Of Harvard College Methods of increasing gene expression through rna protection
WO2009046397A2 (en) * 2007-10-04 2009-04-09 Board Of Regents, The University Of Texas System Modulating gene expression with agrna and gapmers targeting antisense transcripts
EP2225377B1 (en) * 2007-11-26 2014-01-08 Santaris Pharma A/S Lna antagonists targeting the androgen receptor
JP2011507554A (en) * 2007-12-28 2011-03-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Methods and compositions for increasing gene expression
JPWO2009093384A1 (en) * 2008-01-24 2011-05-26 独立行政法人産業技術総合研究所 Polynucleotide, polynucleotide analogue and gene expression control method using the same
AU2009235941A1 (en) * 2008-04-07 2009-10-15 Riken RNA molecules and uses thereof
US8669102B2 (en) * 2008-08-14 2014-03-11 Isis Pharmaceuticals, Inc. Modulation of prion expression
US8815586B2 (en) * 2009-04-24 2014-08-26 The Board Of Regents Of The University Of Texas System Modulation of gene expression using oligomers that target gene regions downstream of 3′ untranslated regions
KR20230137491A (en) * 2009-11-12 2023-10-04 더 유니버시티 오브 웨스턴 오스트레일리아 Antisense Molecules and Methods for Treating Pathologies
DK2558578T3 (en) * 2010-04-13 2016-01-25 Life Technologies Corp CONFIGURATIONS AND METHODS FOR INHIBITION OF nucleic acid function
US20110306653A1 (en) * 2010-05-14 2011-12-15 Tagcyx Biotechnologies Stabilization method of functional nucleic acid
GB201010557D0 (en) * 2010-06-23 2010-08-11 Mina Therapeutics Ltd RNA molecules and uses thereof
CA2865468C (en) * 2011-03-11 2021-05-04 Sarissa Inc. Methods of treating cancer by inhibition of dna repair proteins
WO2012138289A1 (en) * 2011-04-08 2012-10-11 Zain-Luqman Rula Diagnosis and treatment of friedreich's ataxia
TWI678375B (en) * 2011-06-09 2019-12-01 可娜公司 Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
EP2756080B1 (en) * 2011-09-14 2019-02-20 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
WO2014043544A1 (en) * 2012-09-14 2014-03-20 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
WO2014144039A1 (en) * 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Characterization of mrna molecules
CN105370259A (en) * 2014-08-29 2016-03-02 中国石油化工股份有限公司 Staged fracturing method of horizontal well
CN107987053B (en) * 2017-12-08 2023-04-14 植恩生物技术股份有限公司 Preparation method of high-purity Z-type flupentixol hydrochloride
CN108590349A (en) * 2018-06-11 2018-09-28 太仓市金毅电子有限公司 Smart lock with tamper-resistant function

Also Published As

Publication number Publication date
AU2014306416A1 (en) 2015-02-19
US20150050738A1 (en) 2015-02-19
US20150225715A1 (en) 2015-08-13
KR20160036065A (en) 2016-04-01
US20170152511A9 (en) 2017-06-01
WO2015023975A1 (en) 2015-02-19
US20150232844A1 (en) 2015-08-20
AU2021203174A1 (en) 2021-06-10
MX2016002044A (en) 2016-08-17
CA2921556A1 (en) 2015-02-19
BR112016003127A2 (en) 2017-10-17
US20150232845A1 (en) 2015-08-20
AU2014306416B2 (en) 2021-02-25
US20150232847A1 (en) 2015-08-20
EP3033424A4 (en) 2017-04-19
IL244081A0 (en) 2016-04-21
AU2014306416A9 (en) 2016-06-16
JP2016528897A (en) 2016-09-23
US20150247144A1 (en) 2015-09-03
EP3033424A1 (en) 2016-06-22
WO2015023975A8 (en) 2016-04-28
US20150232846A1 (en) 2015-08-20
EA201690403A1 (en) 2016-07-29
CN105658797A (en) 2016-06-08
US20150247145A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
IL273205A (en) Compositions and methods
IL277196B (en) Methods and compositions for genome engineering
IL244081A0 (en) Compositions and methods for modulating rna
IL269461B (en) Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto
GB2520795B (en) Compositions and methods
SMT201900635T1 (en) Compositions and methods for activating
EP2951283A4 (en) Compositions and methods
GB201308072D0 (en) Compositions and methods
IL241439B (en) Compositions and methods for modulating tau expression
AP2014008100A0 (en) Compositions and methods for modulating hemoglobingene family expression
IL241957B (en) Microrna compounds and methods for modulating mir-122
ZA201506874B (en) Binder compositions and methods for making and using same
IL244082A0 (en) Compositions and methods for modulating dna methylation
GB201305414D0 (en) Method and composition
GB201305813D0 (en) Compositions and methods
ZA201506873B (en) Binder compositions and methods for making and using same
IL239680A0 (en) Compositions and methods for polynucleotide transferction
EP2964610A4 (en) Vinylsulfone-based 18f-labeling compositions and methods and uses thereof
SG11201510147VA (en) Methods and compositions for enhancing cognitive performance
GB201322617D0 (en) Methods and compositions
GB201312393D0 (en) Compositions and Methods
AU2013902874A0 (en) Compositions and methods
HK1217608A1 (en) Methods and compositions for consumables